{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:10:14Z","timestamp":1756303814439,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,3,22]]},"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>A woman in her mid-70s with metastatic pancreatic adenocarcinoma presented with fatigue, nausea and bilateral leg swelling, 4\u2009days after an intravenous gemcitabine infusion. Additional examination and laboratory tests showed mild hypertension, low haemoglobin, high lactate dehydrogenase, low platelet count and high serum creatinine. The patient was subsequently diagnosed with haemolytic uraemic syndrome (HUS), and gemcitabine administration was immediately ceased. The patient received a 5-day course of methylprednisolone, with a full recovery being made 10 days after diagnosis. Clinicians should be aware of the rare but serious complication of gemcitabine-induced HUS (GiHUS), as early diagnosis and management, which includes prompt discontinuation of gemcitabine, are crucial in promptly resolving this condition. This case report describes one treatment that can be used for the treatment of GiHUS, while briefly covering some other novel treatments that have been described in other studies.<\/jats:p>","DOI":"10.1136\/bcr-2018-228363","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T12:48:03Z","timestamp":1554727683000},"page":"e228363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-4319","authenticated-orcid":false,"given":"Adarsh","family":"Das","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint John of God Hospital Subiaco, Subiaco, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Clay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint John of God Hospital Subiaco, Subiaco, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.1","DOI":"10.3322\/CA.2007.0010"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.2","DOI":"10.1056\/NEJMoa1304369"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.3","DOI":"10.1634\/theoncologist.2009-0272"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.4","DOI":"10.1056\/NEJMra0902814"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.5","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.6","DOI":"10.5414\/CNP71130"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.7","DOI":"10.1007\/s00277-004-0938-8"},{"key":"2025082706461629000_12.4.e228363.8","first-page":"340","article-title":"Atypical hemolytic-uremic syndrome: the interplay between complements and the coagulation system","volume":"7","author":"Nayer","year":"2013","journal-title":"Iran J Kidney Dis"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.9","DOI":"10.1186\/1750-1172-6-60"},{"key":"2025082706461629000_12.4.e228363.10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","article-title":"Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature","volume":"8","author":"Lee","year":"2014","journal-title":"Gut Liver"},{"key":"2025082706461629000_12.4.e228363.11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3123-6","article-title":"Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review","volume":"79","author":"Ritchie","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.12","DOI":"10.1179\/1973947813Y.0000000122"},{"key":"2025082706461629000_12.4.e228363.13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.12659\/AJCR.882858","article-title":"Gemcitabine induced hemolytic uremic syndrome","volume":"13","author":"Sadjadi","year":"2012","journal-title":"Am J Case Rep"},{"key":"2025082706461629000_12.4.e228363.14","first-page":"1676","article-title":"[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer]","volume":"107","author":"Wato","year":"2010","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"2025082706461629000_12.4.e228363.15","first-page":"369","article-title":"Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature","volume":"6","author":"Saif","year":"2005","journal-title":"JOP"},{"key":"2025082706461629000_12.4.e228363.16","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"2025082706461629000_12.4.e228363.17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/08860220903118582","article-title":"A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke","volume":"31","author":"Phelan","year":"2009","journal-title":"Ren Fail"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.18","DOI":"10.1093\/ndtplus\/sfr031"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.19","DOI":"10.1016\/S0272-6386(99)70194-0"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.20","DOI":"10.1007\/s00277-007-0429-9"},{"key":"2025082706461629000_12.4.e228363.21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10157-013-0911-8","article-title":"Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the japanese society of nephrology and the japan pediatric society","volume":"18","author":"Sawai","year":"2014","journal-title":"Clin Exp Nephrol"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.22","DOI":"10.1159\/000013525"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.23","DOI":"10.1093\/ndt\/14.10.2523"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.24","DOI":"10.1007\/BF00873232"},{"key":"2025082706461629000_12.4.e228363.25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MCG.0b013e31802da22e","article-title":"Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer","volume":"42","author":"Boeck","year":"2008","journal-title":"J Clin Gastroenterol"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.26","DOI":"10.1007\/s00280-008-0900-x"},{"key":"2025082706461629000_12.4.e228363.27","first-page":"127","article-title":"Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura","volume":"6","author":"Franchini","year":"2008","journal-title":"Blood Transfus"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.28","DOI":"10.1016\/S1470-2045(07)70203-6"},{"key":"2025082706461629000_12.4.e228363.29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1590\/S0101-28002010000300013","article-title":"Thrombotic microangiopathies: thrombotic thrombocytopenic purpura \/ hemolytic uremic syndrome","volume":"32","author":"Polito","year":"2010","journal-title":"J Bras Nefrol"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.30","DOI":"10.1111\/imj.12261"},{"key":"2025082706461629000_12.4.e228363.31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.patbio.2015.03.001","article-title":"Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome","volume":"63","author":"Picard","year":"2015","journal-title":"Pathol Biol"},{"key":"2025082706461629000_12.4.e228363.32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.12998\/wjcc.v6.i12.531","article-title":"Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature","volume":"6","author":"Cidon","year":"2018","journal-title":"World J Clin Cases"},{"doi-asserted-by":"crossref","unstructured":"Werner J , Herzig S . Paraneoplastic syndromes in pancreatic cancer: Springer New York. 2018:633\u201357.","key":"2025082706461629000_12.4.e228363.33","DOI":"10.1007\/978-1-4939-7193-0_27"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.34","DOI":"10.1007\/s00467-010-1556-4"},{"doi-asserted-by":"publisher","key":"2025082706461629000_12.4.e228363.35","DOI":"10.1007\/s00467-008-0964-1"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-228363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T13:46:27Z","timestamp":1756302387000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-228363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,8]]},"published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1136\/bcr-2018-228363"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-228363","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}